These findings may be particularly captivating for the possible clinical employment of renalase during the course of COVID-19, considering that by shifting the balance between ERK1/2 and JNK activation towards increased ERK1/2 and PI3K/Akt activation, the cells will presumably overcome and survive oxidative damage [93]. This evidence concerns the gene AKT1 and COVID-19.